Clinical Trial

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

Name: D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC — clinical trial record (NCT06643208)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-10-13.

Trial Details

NCT Number	NCT06643208
Lead Sponsor	Fujian Provincial Hospital
Conditions	Intrahepatic Cholangiocarcinoma
Enrollment	37 participants
Start Date	2024-07-01
Primary Completion	2027-01-01 (estimated)
Study Completion	2027-03-01 (estimated)
Updated on ClinicalTrials.gov	2025-06-26